A plausible strategic outcome is that Novartis acquires both Hikma and Amarin precisely to resolve, not perpetuate, the infringement overhang: by owning both sides, Novartis could immediately terminate Vascepa-related generic challenges, withdraw or settle “skinny-label” exposure, and ring-fence or divest Hikma’s conflicted assets, restoring full branded integrity to Amarin’s franchise. In that scenario, the litigation disappears overnight, pricing power and physician confidence are stabilized, and Vascepa becomes a clean, globally scalable cardiovascular asset inside Novartis—while Hikma’s remaining generics operate independently without IP friction. The net effect would be the elimination of uncertainty that has long discounted Amarin’s valuation, turning a legal standoff into a strategic consolidation that benefits shareholders and accelerates long-term growth.
Market Data 
Markets 
AI
